Brilinta
PreclinicalSmall molecule
AstraZenecaBrilinta is one of 86 small molecule programs targeting Acute Coronary Syndrome. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
114 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Lopid
PfizerApproved
Adempas
BayerApproved
Jardiance
Boehringer IngelheimApproved
Pletal
OtsukaApproved
Colcrys
Jazz PharmaceuticalsPhase 3
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Inomax
MMallinckrodt
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Brilinta. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company